Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
The manuscript describes a methodology for the establishment as well as longitudinal growth monitoring of spontaneous lung metastasis from orthotopically-injected breast tumors, amenable to intervention at all stages of the metastatic cascade.
Metastasis remains the primary cause of cancer-related death. The succession of events that characterize the metastatic cascade presents multiple opportunities for therapeutic intervention, and the ability to accurately model them in mice is critical to evaluate their effects. Here, a step-by-step protocol is presented for the establishment of orthotopic primary breast tumors and the subsequent monitoring of the establishment and growth of metastatic lesions in the lung using in vivo bioluminescence imaging. This methodology allows for the evaluation of treatment or its biological effects along the entire range of metastatic development, from primary tumor escape to outgrowth in the lungs. Breast orthotopic tumors are generated in mice via injection of a luciferase-labeled cell suspension in the 4th mammary gland. Tumors are allowed to grow and disseminate for a specific amount of time and are then surgically resected. Upon resection, spontaneous lung metastasis is detected, and the growth over time is monitored using in vivo bioluminescence imaging. At the desired experimental endpoint, lung tissue can be collected for downstream analysis. The treatment of established, clinically evident metastasis is critical to improve outcomes for stage IV cancer patients, and it can be evaluated through tail vein models of experimental lung metastasis. However, metastatic dissemination occurs early in breast cancer, and many patients have latent, subclinical disseminated disease after surgery. Utilization of spontaneous models such as this one provides the opportunity to study the whole spectrum of the disease, especially the systemic effects driven by treatment of the primary tumor such as pre-metastatic niche priming, and evaluate treatments on dormant and subclinical disease after surgery.
Metastasis - the spread of cancer cells from the primary tumor to other parts of the body - remains the cause of death in more than 90% of cancer patients. This process is complex, involving migration of the tumor cells out of the primary tumor and intravasation into the circulation, survival in the blood, extravasation and survival in the target organ, re-instauration of the proliferative state, and outgrowth1. Spontaneous and transplantable murine cancer models have been used to investigate early or late stages of metastasis, each presenting its own advantages and disadvantages, which have been thoroughly discussed2
All animal procedures and protocols described here were approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University.
1. Preparation of cells for injection
Orthotopic injection of mouse cancer cell lines into the 4th mammary fat pad of mice is a reproducible and reliable procedure for inducing mouse primary tumors. Utilizing the EO771 cell line transduced with luciferase in the conditions described in this protocol, primary tumors become palpable and can be measured using calipers about 7 days after injection and reach approximately 150 mm3 in volume at around 14 days following initial injection (Figure 1). Bioluminescence growth of .......
As the early nature of metastatic dissemination and the systemic effects of cancer become more widely recognized, the need for models in which both of these critical factors are taken into consideration becomes a necessity. This protocol allows researchers to monitor minimal residual disease and outgrowth of lung metastasis occurring spontaneously from primary breast tumors, accounting for the systemic effects of cancer that influence the metastatic process. Primary tumor removal is necessary to evaluate lung metastasis .......
The authors have nothing to disclose.
Work in the Bos lab is supported by the Susan G. Komen Foundation (CCR18548205 P.D.B.), V Foundation (V2018-22 P.D.B.), and American Cancer Society (RSG-21-100-01-IBCD P.D.B.)
....Name | Company | Catalog Number | Comments |
0.25% Trypsin/EDTA | Hyclone | SH30042.01 | |
1.5ml microcentrifuge tubes | USA Scientific | 1615-5500 | |
10% povidone-iodine solution | Medline | MDS093906 | |
15ml centrifuge tubes | VWR | 89039-666 | |
1X PBS | Hyclone | SH30256.01 | |
28G 0.5ml U-100 Insulin Syringe | BD Biosciences | 329461 | |
Amphotericin B | Gemini Bio-products | 400-104 | |
Cautery Kit | Braintree Scientific | DEL2 | |
D-Luciferin Potassium | SydLabs | MB102 | |
Ethanol | Koptec | V1001 | |
Fetal Bovine Serum | R&D Systems | S11150H | |
Forceps | Fisherbrand | 16-100-110 | |
Growth factor-reduced Matrigel | Corning | 354230 | |
Isoflurane | Covetus | 29405 | |
IVIS Spectrum 200 | Perkin Elmer | 124262 | |
Meloxicam (2mg/ml) | Zoopharm LLC | N/A | By veterinary prescription |
Penicillin/Streptomycin | Gemini Bio-products | 400-109 | |
RPMI1640 | Hyclone | SH30027.01 | |
Scissors | Miltex | 5-300 | |
Silk sutures | Braintree Scientific | SUT-S 103 | |
Surgical staples | Reflex7 | 203-1000 | |
Trypan Blue | Gibco | 15250-061 |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone